Johnson & Johnson Stock Holds Steady at $268 Amid FY 2026 Earnings Outlook Confirmation

Johnson & Johnson stock held steady at $268 per share as of August 29, 2026, following the company's confirmation of its FY 2026 earnings outlook. The pharmaceutical giant set a guidance range of $11.60 to $11.75 in earnings per share for the current year, with analysts collectively projecting EPS of $11.61.

According to analyst data, Johnson & Johnson has a Moderate Buy rating from covering analysts, with 19 Buy ratings and 6 Hold ratings. The mean price target is $276.29, indicating potential upside of 3.1% from the current share price.

The company's stock has shown resilience in recent months, with a year-to-date gain of 28.38% as of August 29, 2026. Johnson & Johnson's dividend profile remains attractive, with an annualized payout of $5.36 and a yield of 2.0%.

Johnson & Johnson continues to engage in research and development across various healthcare products, including innovative pharmaceuticals and medical devices. The company is working on first-in-class therapies for rare anemia indications, aiming to bring new standards of care to patients living with chronic conditions.